Thermo Fisher Raises 2026 Revenue and EPS Outlook, Citing Strong Performance
Summary
Thermo Fisher Scientific raised its full-year 2026 revenue outlook to $47.3 billion-$48.1 billion and adjusted EPS view to $24.64-$25.12 during its recent conference call. This positive revision to guidance is a significant development for investors, indicating stronger expected performance than previously anticipated. While an executive noted expectations for modest inflationary pressure from the Middle East conflict and acknowledged market conditions for the instruments business remain below normal due to U.S. and China academic/government environments, the overall outlook is robust. The company also highlighted that AI is expected to improve ROI for the drug development industry, potentially enhancing funding interest for biotechs. Traders will focus on the updated guidance as a key driver for the stock.
At the time of this announcement, TMO was trading at $460.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $171.2B. The 52-week trading range was $385.46 to $643.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.